Mild behavioral impairment (MBI) describes the emergence of later-life neuropsychiatric symptoms (NPS) as an at-risk state for incident cognitive decline and dementia, and for some as a potential manifestation of prodromal dementia. How NPS mechanistically link to the development of mild cognitive impairment and Alzheimer's disease (AD) is not fully understood, with potential mechanisms including shared risk factors related to both NPS and cognitive impairment, or AD pathology promoting NPS. This is the first exploratory study to examine whether AD genetic loci as a genetic risk score (GRS), or individually, are a shared risk factor with MBI. Participants were 1,226 older adults (aged 72-79; 738 males; 763 normal cognition) from the Personality and Total Health Through Life project. MBI was approximated in accordance with Criterion 1 of the ISTAART-AA diagnostic criteria using a transformation algorithm for the neuropsychiatric inventory. A GRS was constructed from 25 AD risk loci. Binomial logistic regression adjusting for age, gender, and education examined the association between GRS and MBI. A higher GRS and APOE*ε4 were associated with increased likelihood of affective dysregulation. Nominally significant associations were observed between MS4A4A-rs4938933*C and MS4A6A-rs610932*G with a reduced likelihood of affective dysregulation; ZCWPW1-rs1476679*C with a reduced likelihood of social inappropriateness and abnormal perception/thought content; BIN1-rs744373*G and EPHA1-rs11767557*C with higher likelihood of abnormal perception/thought content; NME8-rs2718058*G with a reduced likelihood of decreased motivation. These preliminary findings suggest a common genetic etiology between MBI and traditionally recognized cognitive problems observed in AD and improve our understanding of the pathophysiological features underlying MBI.
precede or accompany the onset of cognitive symptoms and clinical diagnosis . The concept of "mild behavioral impairment" (MBI) describes the emergence of later-life sustained NPS as an at-risk state for cognitive decline and dementia and as a potential manifestation of prodromal dementia (Ismail et al., 2016) .
How NPS mechanistically link to the development of mild cognitive impairment (MCI) and Alzheimer's disease (AD) is not fully understood. Five potential models have been proposed (Geda et al., 2013; Geda, Krell-Roesch, Sambuchi, & Michel, 2017) LOAD has a large genetic component, with genetic variants accounting for 53% of the total phenotypic variance of LOAD (Ridge et al., 2016) . The Apolipoprotein (APOE) epsilon 4 (*ε4) allele confers the largest known genetic risk for LOAD, with a 2-3 and 10-12 times increased risk for heterozygotes and homozygotes, respectively (Farrer et al., 1997) . Beyond APOE, genome wide association studies (GWAS), have identified single nucleotide polymorphisms (SNPs) at a further 23 loci associated with LOAD (Harold et al., 2009; Hollingworth et al., 2011; Lambert et al., 2009 Lambert et al., , 2013 Naj et al., 2011; Seshadri et al., 2010; Supporting Information Table S1 ). These loci are clustered in biological pathways that are play an important role in the development of cognitive impairment and dementia, and are involved in the accumulation of the neuropathological features (amyloid beta [Aβ] and neurofibrillary tangles) of LOAD. The neuropathological features of LOAD have also been associated with greater impairment over time in NPS, and depression specifically, in cognitively normal and demented subjects (Babulal et al., 2016; Roe, Fagan, Grant, Holtzman, & Morris, 2013; .
As such, LOAD risk loci may also be associated with the development of NPS, although, at present the role of LOAD risk loci in the development of NPS is unclear. Most research to date has focused on the association of APOE with individual NPS in dementia, with APOE-NPS associations reported for depression, anxiety, apathy, delusions/ hallucinations, and agitation/aggression (Panza et al., 2012) . However, contrasting findings have been observed between studies on the association between APOE and affective symptoms (depression and anxiety), while there is limited cross-sectional evidence to suggest an association between apathy, agitation/aggression, and delusions/hallucinations that has not been replicated in longitudinal studies (Panza et al., 2012) . To the best of our knowledge, no study has examined the role of non-APOE LOAD risk loci with the development of NPS.
Here we conduct an exploratory study to investigate the association of a genetic risk score (GRS) composed of genome-wide significant SNPs associated with LOAD and MBI. Additionally, we assess whether the individual SNPs are associated with MBI in 1,226 MBI and nondemented community dwelling adults.
| METHODS

| Participants
Participants of this study were community dwelling older adults who were recruited into a longitudinal study of health and wellbeing, the Personality and Total Health Through Life project (PATH). The background and test procedures for PATH have been described in Anstey et al. (2012) . We used data from the PATH Wave 4 60+ cohort. 
| Cognitive function and clinical diagnosis
The diagnostic procedure used to determine cognitive function states and clinical diagnoses at Wave 4 are published elsewhere (Eramudugolla et al., 2017; . In summary, for the 1,644 participants assessed at Wave 4, their data was screened for signs of decline based on the following criteria: a previous PATH diagnosis of dementia or a mild cognitive disorder, or evidence of current objective cognitive impairment (based on performance ≤6.7th percentile on at least one cognitive measure, or mini mental state examination [MMSE] <24), and evidence of subjective decline on the Memory and Cognition Questionnaire (MAC-Q; Crook, Feher, & Larrabee, 1992) or decline on the MMSE of >3 points because of Wave 3 or consistent MMSE <24 at Waves 3 and 4 (Eramudugolla et al., 2017).
For participants who showed signs of cognitive impairment, as detailed above, an algorithm that combined neurocognitive assessments, informant data, and self-reported medical history was used to operationalize criteria for Diagnostic and Statistical Manual (DSM-V) major and mild neurocognitive disorder (NCD), DSM-IV dementia, and MCI. Diagnoses were confirmed by a case file review by a research neurologist and consensus diagnosis with a clinician specializing in Psychiatry. Case files were reviewed by the research neurologist and included neuropsychological test data, informant data, structural brain MRI scans (where available) to aid differential diagnosis of dementia subtypes, self-reported medication list, and contact of participant for further clarification of details relevant to diagnosis (Eramudugolla et al., 2017) . Inter-rater reliability indicated high agreement between the neurologist and psychiatrist in the independent review of a subsample of 29 cases (Eramudugolla et al., 2017) .
MCI was assessed using the Winblad (Winblad et al., 2004) criteria for MCI. Subjects were considered "cognitively normal, but-atrisk" (CN-AR) if they neither met the Winblad criteria for MCI or the DSM-IV criteria for dementia, but demonstrated signs of impairment as identified by the screening criteria outlined above (Eramudugolla et al., 2017) . Individuals who did not meet any of the above criteria were classified as cognitively normal.
| Informant interview
Informants were nominated by the PATH participant and provided information on the participant's physical and mental health via a telephone interview. Informants were predominantly spouses (49.4%), children (33.8%), or a close friend (9.7%; .
The informant interview included the NPI (Cummings et al., 1994) , to assess the presence and severity of dementia related behavioral symptoms, over 1 month, in 10 neuropsychiatric domains (delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, and aberrant motor activity) and two neurodegenerative domains (night-time behavioral disturbances and appetite and eating abnormalities).
| Mild behavioral impairment
The NPS Professional Interest Area of the International Society to Advance Research and Treatment (ISTAART), a subgroup of the Alzheimer's Association (AA), has developed and published research diagnostic criteria for MBI. According to the operationalized criteria (Ismail et al., 2016) , MBI is a neurobehavioral syndrome hallmarked by changes in behavior or personality which start in later-life (after the age of 50 years), are sustained for at least 6 months, and represent a clear change from the person's usual behavior or personality. MBI is a validated construct, separate from psychiatric illness, demonstrating a significantly higher 5-year progression rate to dementia than late life psychiatric disorders (Taragano et al., 2018) . Further, in those with no cognitive impairment or MCI, the presence of MBI is associated with a significantly higher 3-year progression to dementia than those without MBI (Cano et al., 2018) . As described in the MBI criteria, and operationalized in the MBI checklist (MBI-C, developed explicitly as a case ascertainment instrument for MBI [Ismail et al., 2017] ), the NPS components of MBI have been clustered into the following domains: decreased motivation, affective dysregulation, impulse dyscontrol, social inappropriateness, and abnormal perception/thought content.
The MBI domains are a way of describing discrete MBI endophenotypes, which may be associated with different neural signatures, and may predict different cognitive and functional outcomes, as well as different dementia pathologies. Importantly, these domains reflect areas of NPS that are shown to be valid and related to the syndromes of cognitive decline (Ismail et al., 2017) , and have been validated in a factor analysis with MBI domains loading onto a 5-factor model in a sample of 10,952 participants administered the checklist (Creese et al., 2018) .
Given the infancy of the MBI-C, it has not yet penetrated large genetic cohorts. In advance of that, an MBI transformation algorithm has been developed to map NPI (Cummings et al., 1994) items onto MBI domains, to approximate Criterion 1 of MBI (albeit with a 1-month reference range), and to facilitate further study and analysis.
This published algorithm has been used to generate MBI Criterion 1 prevalence estimates in community Sheikh et al., 2018) and clinical (Sheikh et al., 2018) 
| Genotyping and genetic risk score
SNPs from 23 loci (ABCA7, BIN1, CD2AP, CD33, CLU, CR1, EPHA1, MS4A4A, MS4A4E, MS4A6A, PICALM, HLA-DRB5, PTK2B, SORL1, SLC24A4-RIN3, DSG2, INPP5D, MEF2C, NME8, ZCWPW1, CELF1, FERMT2, and CASS4; Supporting Information Table S1 ) were genotyped using TaqMan OpenArray assays as previously described (Andrews, Das, Anstey, & Easteal, 2017; Andrews, Das, Cherbuin, Anstey, & Easteal, 2016) , in addition to the two SNPs defining the APOE alleles which were genotyped using TaqMan assays as previously described (Jorm et al., 2007) . These SNPs were selected based on their on their genome-wide significant association with LOAD (Harold et al., 2009; Hollingworth et al., 2011; Lambert et al., 2009 Lambert et al., , 2013 Naj et al., 2011; Seshadri et al., 2010) . All SNPs were in HardyWeinberg equilibrium and genotype frequencies are reported in Supporting Information Table S2. For the GRS analysis, SNPs were coded additively according to the number of risk alleles, whereas for the single SNP analysis, variants were coded additively according to the number of minor alleles (Supporting Information Table S1 ). The APOE *ε2 and APOE *ε4 alleles were assumed to be dominant to the APOE *ε3 allele. APOE alleles were coded as APOE *ε2+ (APOE *ε2/ε3 + APOE *ε2/ε2), APOE *ε4+ (APOE *ε4/ε3 + APOE *ε4/ε4) or APOE *ε3/ε3. Participants with the APOE *ε2/ε4 allele were excluded to avoid conflation between the APOE *ε2 protective and APOE *ε4 risk effects.
Using the LOAD risk SNPs, an OR weighted genetic risk score (OR-GRS) was constructed, which is the sum of all the risk alleles across the individual, weighted by the odds ratio (Che & MotsingerReif, 2013 ). The OR-GRS is calculated according to the following formula: ORGRS ¼ P I i¼1 log OR ij À Á *G ij for the ith patient, where log (OR ij ) = the log of the odds ratio for the jth SNP and G ij = the number of risk alleles for jth SNP. GRS were not calculated for individuals with missing genetic data (n = 93). We weighted the LOAD risk SNPs using the previously reported OR for LOAD (Supporting Information Table S1 ). As APOE is known to have the largest effect size for LOAD, the OR-GRS was also calculated excluding APOE to determine the effect of the GRS beyond that of APOE. The OR-GRS was transformed into a z-score.
| Data analysis
All analysis was performed in the R 3.3.2 Statistical computing environment. The association of the LOAD GRS with MBI domains was examined using logistic regression models adjusting for age, gender, and years of education. Individual SNPs were similarly assessed, with each model only including a single SNP. Because 25 loci (APOE ε2, APOE ε4, and 23 LOAD GWAS SNPs) and 1 GRS were tested, p < .0019 was considered to be study wide significant after Bonferroni correction. p < .05 and >.0019 was considered nominally significant.
As a sensitivity analysis, the above models were rerun: (a) with cognitive status included as a covariate and (b) with CN-AR and MCI participants excluded.
3 | RESULTS
| Population characteristics of the PATH cohort
Descriptive characteristics of the Wave 4 PATH cohort are presented in 
| Association of an AD GRS with MBI
A binomial logistic regression was performed to evaluate the effects of the OR-GRS on the likelihood of participants exhibiting MBI symptoms (Table 2) . Increasing OR-GRS was associated with an increased likelihood of exhibiting affective dysregulation, with a 1SD increase having a 1.23 higher odds (p = .0033). However, when APOE was excluded from the OR-GRS, it was no longer significantly associated with any of the MBI domains.
| Association of AD related genetic variants with MBI
We further evaluated the effects of the individual SNPs on MBI (Table 2 ). The only association that withstood correction for multiple testing was the association of the APOE*ε4 allele with an increased likelihood of affective dysregulation (p = .0018). Nominally significant associations were observed for MS4A4A*C and MS4A6A*G with a reduced likelihood of affective dysregulation; NME8*G with a reduced likelihood decreased motivation; ZCWPW1*C with a reduced likelihood social inappropriateness and abnormal perception/ thoughts; BIN1*G and EPHA1*C with an increased likelihood of abnormal perception/thoughts.
| Sensitivity analysis
The effect of the OR-GRS or individual SNPs on the likelihood of exhibiting behavioral symptoms as assessed by the NPI are presented in Supporting Information Table S3 . These results are largely nonsignificant and would not withstand correction for multiple testing.
Including cognitive status as a covariate in the models did not markedly change the results (Supporting Information Table S4 ) for the association of the AD genetic loci with MBI. When assessing the associations in CN participants only (Supporting Information Table S5 ), the results were largely similar, though some differences were observed, with ZCWPW1*C no longer associated with abnormal perception/ thought control; FERMT2*C been associated with a decreased risk of impulse dyscontrol; and HLA-DRB1*T associated with an increased risk of impulse dyscontrol and abnormal perception/thoughts.
When assessing the SNP-MBI associations in CN-AR and MCI
participants, only the OR-GRS and BIN1 were still associated with an increased risk of affective dysregulation and abnormal perception or thought control, respectively (Supporting Information Table S6 ). However, the previous associations for APOE ε4, NME8, MS4A4E, MS4A6A, ZCWPW1, and EPHA1 were no longer significant, although the OR trended in the same direction. Additionally, significant associations not observed in the full analysis were found for PTK2B*C and decreased risk of affective dysregulation; NME8*G and decreased risk of affective dysregulation and social inappropriateness; and CD2AP*C and decreased risk of social inappropriateness.
| DISCUSSION
In this study, we investigated whether a genetic risk scored composed of genome-wide significant LOAD risk loci was associated with MBI symptoms in a cohort of CN participants. A weighted GRS was associated with affective dysregulation; however, this association was attenuated when APOE was excluded from the GRS, indicating that the association was driven by the dominant effect of the APOE*ε4
allele. We further investigated whether the individual loci were associated with the MBI domains and identified three loci (APOE, MS4A4A, and MS4A6A) associated with affective dysregulation, one locus (NME8) associated with Decreased Motivation, one locus (ZCWPW1) associated with social inappropriateness, and three loci (BIN1, EPHA1, and ZCWPW1) associated with abnormal perception/thought control.
The majority of these findings, however, were nominally significant (p < .05 and >.0019), with only the APOE-affective dysregulation association significant after multiple testing (p = .0018).
The association between APOE and depression in populationbased studies and in dementia patients has been widely investigated in the literature; however, the results between studies are mixed (Panza et al., 2012; Skoog et al., 2015) . A recent meta-analysis including 13 studies of late-life depression found that the APOE ε4 allele significantly increased risk of depression (Feng et al., 2015) . Furthermore, a longitudinal population based analysis found that the APOE ε4 allele was associated with incident minor depression and depression symptom severity over 5 years, even after excluding participants who Note. Bold indicates significant associations after adjusting for multiple testing (p < .0019). ***p < .001.; **p < .01.; *p < .05.
developed dementia within 9 years . The results from our analysis provide additional support for APOE promoting increased risk of late-life depression, although further longitudinal analysis is needed to verify these findings. This additional analysis is needed as it remains unclear whether depression is a risk factor of AD and dementia or an early manifestation of AD brain pathology (Lanctot et al., 2017) .
The mechanisms underlying the increased risk of depression in APOE ε4 carriers are not fully understood, while several potential mechanisms been implicated. First, brain atrophy may act as an intermediating factor, with APOE ε4 carriers exhibiting greater medial temporal lobe atrophy (Liu, Kanekiyo, Xu, & Bu, 2013) . Temporal lobe atrophy has also been associated an increased risk of incident major depression independently of dementia (Gudmundsson et al., 2015) .
Second, APOE is associated with cerebrovascular dysfunction (Tai et al., 2016) , while late-life depression is associated with increased cerebrovascular comorbidities and microvascular lesions (Aizenstein et al., 2016) . This suggests that cerebrovascular dysfunction induced by the APOE ε4 may increase cerebrovascular damage leading to increased depressive symptoms. Third, APOE influences amyloid-β (Aβ) aggregation, deposition, and clearance, with the ε4 allele associated with increased Aβ levels and plaque burden (Liu et al., 2013) .
Increased Aβ levels have also been associated with depression and worsening depressive symptoms over time (Harrington, Lim, Gould, & Maruff, 2015; Roe et al., 2013) . This may be driven by a neuroinflammatory response as a result of microglial activation by Aβ (Heneka et al., 2015) , promoting the release of inflammatory cytokines that interferes with neurotransmitters and neurocircuitry, leading to depressive symptoms (Miller & Raison, 2016) .
In addition to APOE, two SNPs within the MS4A locus were nominally associated with a decreased risk of affective dysregulation. The function of the proteins encoded by the genes within the MS4A gene cluster is not well characterized, however recent reports have suggested a putative role in the immune system by promoting activation of microglia and the release of proinflammatory cytokines (Efthymiou & Goate, 2017; Eon Kuek, Leffler, Mackay, & Hulett, 2016; Ma, Yu, & Tan, 2015) . Inflammation impacts the synaptic availability of the monoamines serotonin, noradrenaline, and dopamine, as well as the excitatory amino acid glutamate that can ultimately affect the neurocircuitry that regulates behavior associated with anhedonia and anxiety, core aspects of depression (Miller & Raison, 2016) . As such, the MS4A putative role in the immune system may influence both AD pathology and depressive symptoms.
BIN1 and EPHA1 were both nominally associated with the MBI domain abnormal perception/thought content. In AD patients with psychosis (AD + P), neuroimaging and postmortem data have indicated an exaggerated prefrontal cortical synaptic deficit (Murray, Kumar, DeMichele-Sweet, & Sweet, 2014) and right frontal atrophy (Ismail, Nguyen, Fischer, Schweizer, & Mulsant, 2012; Ting et al., 2015) . Greater synapse loss and/or atrophy in AD + P may be a result of either increased accumulation of pathology in AD + P or from enhanced synaptic vulnerability to this pathology because of other molecular changes (Murray, Kumar, et al., 2014) . In agreement with this, tau pathology has been consistently shown to be increased in AD + P Murray, Kumar, et al., 2014) . The association between BIN1 and tau pathology has been firmly established, where BIN1 knockdown in a Drosophila model suppressed taumediated neurotoxicity, while in human neuroblastoma cell lines and the mouse brain BIN1 and tau were observed to colocalize and interact (Chapuis et al., 2013) . Accordingly, BIN1 has been associated increased neurofibrillary tangle burden (Beecham et al., 2014) . The results from this analysis suggest that BIN1 may influence tau pathological burden, promoting synaptic loss and the development of psychotic symptoms within the prodromal phase of dementia. The role of EPHA1 in AD is not well-understood, however, it is highly expressed in the adult brain and plays a role in synaptic formation and plasticity, axonal guidance, and brain development (Davy et al., 1999; Lai & Ip, 2009; Martínez, Otal, Sieber, Ibáñez, & Soriano, 2005) . This suggests that variants in EPHA1 may enhance synaptic vulnerability to AD pathology, and corresponding psychotic symptoms. However, these results should be interpreted with caution. A recent genome wide association study of AD + P did find that both BIN1 and EPHA1 were associated with AD + P when contrasting to controls, however, no association was observed when contrasting AD + P to AD -P (Hollingworth et al., 2012) . This suggests that both loci are associated with AD irrespective of psychotic symptoms, though this analysis did have limited power.
Finally, we observed a nominally significant decreased risk for NME8 with decreased motivation and ZCWPW1 with a decreased risk of social inappropriateness and abnormal perception/thought control. The role of NME8 and ZCWPW1 in AD is not well characterized, with both loci relatively understudied (Karch & Goate, 2015) .
NME8 has been previously associated with nonneurological related diseases (Liu et al., 2014) , and recently with cognitive decline, elevated CSF tau, and hippocampal atrophy (Liu et al., 2014) . The pathophysiology of apathy in AD is characterized by dysfunctions in the prefrontal cortex, orbitofrontal cortex, anterior cingulate cortex, amygdala, and basal ganglia, particularly in regard to corticosubcortical circuits involving dopaminergic and cholinergic pathways Tascone & Bottino, 2013) .
As with NME8, the function of ZCWPW1 is unknown, though the index SNP was shown to have functional evidence as an expression quantitative trait locus for PILRB, which is expressed in microglia and is involved in the regulation of immune response (Karch, Ezerskiy, Bertelsen, & Goate, 2016) . The neurobiological correlates of disinhibition in AD include orbitofrontal-subcortical circuit dysfunction that impairs social cognitive abilities and loss of control over reactions (Tascone & Bottino, 2013; Wijngaarden et al., 2017) . Because of the scarcity of studies investigating the role of NME8 and ZCWPW1, the possible underlying mechanisms for their associations with the MBI domains are not known.
The results from this study should be interpreted in conjunction with some study limitations. First, this is an exploratory candidate gene study that is relatively large in the context of clinical studies, in comparison to many genome-wide associations studies the sample size is small. As a general guideline, an approximate sample size of 900 cases and 900 controls is required to detect an odds ratio of 1.3 at 90% power with an α of 0.05 and an allele frequency of 20%.
Increasing the α to 5 × 10 −8 (genome-wide significance) to account for multiple testing would require a sample size of approximately 4,000 cases and 4,000 controls (Colhoun, McKeigue, & Davey Smith, 2003; Hattersley & McCarthy, 2005) . Low statistical power because of small sample size can contribute to unreliable findings as a result of: (a) the low probability of finding true effects; (b) a lower probability that an observed effect that is statistically significant reflects a true effect; and (c) an exaggerated estimate of the magnitude of an affect with a true effect is discovered (Button et al., 2013) . As such, the findings in this study do need to be replicated in a larger cohort. Second, MBI was approximated using the NPI rather than the recently published MBI-C (Ismail et al., 2017 ; available at www.MBItest.org). The NPI rating scales are designed to assess NPS in dementia, and as such might not be sensitive to milder symptomology in functionally independent community dwelling adults for which the MBI-C was developed (Ismail et al., 2017) . Additionally, the NPI assesses NPS over a short reference time periods that maybe confounded by transient reactive states (e.g., sleep deprivation, medications, and adversity) when used in the context of prodromal states (Ismail et al., 2017) .
Thus, MBI in our study is an approximation of MBI Criterion 1, using a 1-month reference range, and a rating scale designed for a dementia population as opposed to a community dwelling population health sample. While we have recently published prevalence data in community and clinical (Sheikh et al., 2018) samples using these criteria Sheikh et al., 2018) , this transformation algorithm has yet to be validated against the MBI-C. This is especially important for domains such as social appropriateness, which are nominally represented by the "disinhibition" item in the NPI, as opposed to more detailed questioning on empathy, tact, and social behavior as described in the MBI-C. Similarly, cognitive, behavioral, and emotional apathy are assessed in the MBI-C, and these distinctions may not be captured in the NPI sample.
Relevant to our findings around the MBI domain of affective/emotional dysregulation, NPI items on dysphoria, euphoria, and anxiety are used in the transformation. Recent evidence has suggested that natural history is very important in assessing the role of depressive symptoms and incident cognitive decline, indirectly validation the MBI notion of later life onset illness being relevant, important and distinct from point or period prevalence of depressive symptoms . Thus, further research using the MBI-C is required, as the nature of the queries (i.e., later life onset of sustained symptoms) may be a very salient feature of dementia prognostication and early detection, when interventions may be more effective .
Third, as the NPS are assessed via informants, the neuropsychiatric data maybe susceptible to recall bias, influenced by the informants' mood, cultural beliefs, denial, or education (de Medeiros et al., 2010) .
Finally, as the neuropsychiatric data were only collected at Wave 4 in PATH, we are unable to conduct longitudinal analysis to assess whether the AD risk loci are associated with progression in NPS.
Despite these limitations, this study had several strengths, including consisting of a large population-based sample, inclusion of all the known GWAS LOAD risk loci and the narrow age-range reduces the influence of age differences on the results.
In conclusion, this is the first study to investigate the association of LOAD genetic risk loci with MBI. We found that five LOAD risk loci (APOE, MS4A, BIN1, EPHA1, NME8, and ZCWPW1) are associated with MBI domains. Nevertheless, the results from this study need to be replicated in independent cohorts to validate our findings, as the APOE-affective dysregulation association is the only test to survive correction for multiple testing. These findings suggest a common genetic etiology between MBI and traditionally recognized memory problems observed in dementia/AD and improve our understanding of the pathophysiological features underlying MBI.
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